PROCEPT BioRobotics (PRCT) Current Deferred Revenue (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of Current Deferred Revenue data on file, last reported at $13.7 million in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $13.7 million, up 39.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.7 million (up 39.83% YoY), and the FY2025 annual result was $13.0 million, up 36.41% from the prior year.
• Current Deferred Revenue rose to $13.7 million in Q1 2026 per PRCT's latest filing, from $13.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $13.7 million in Q1 2026 and troughed at $1.4 million in Q1 2022.
• A 5-year average of $6.8 million and a median of $5.9 million in 2024 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue soared 188.23% in 2023, then surged 33.5% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $2.9 million in 2022, then surged by 98.11% to $5.7 million in 2023, then surged by 69.11% to $9.6 million in 2024, then jumped by 36.41% to $13.0 million in 2025, then climbed by 5.01% to $13.7 million in 2026.
• Business Quant data shows PRCT's Current Deferred Revenue at $13.7 million in Q1 2026, $13.0 million in Q4 2025, and $10.7 million in Q3 2025.